Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Infusions, Intravenous"" wg kryterium: Temat


Tytuł :
Continuous versus single shot adductor canal block for postoperative pain relief after total knee arthroplasty: A protocol for randomized controlled trial.
Autorzy :
Tao Y; Department of Anesthesiology.
Mao Q; Department of Orthopedics Centre.
Wang J; Department of Critical Medicine, Sunshine Union Hospital, Shandong, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Apr; Vol. 99 (17), pp. e19918.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Clinical Protocols*
Arthroplasty, Replacement, Knee/*adverse effects
Infusions, Intravenous/*standards
Nerve Block/*standards
Adult ; Aged ; Arthroplasty, Replacement, Knee/methods ; Double-Blind Method ; Female ; Humans ; Infusion Pumps/standards ; Infusions, Intravenous/methods ; Male ; Middle Aged ; Nerve Block/methods ; Pain Management/methods ; Pain Management/standards ; Pain, Postoperative/drug therapy ; Prospective Studies ; Randomized Controlled Trials as Topic/methods ; Registries
Czasopismo naukowe
Tytuł :
New Drug Approved for HER2-positive Metastatic Breast Cancer.
Autorzy :
Aschenbrenner DS; Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: .
Pokaż więcej
Źródło :
The American journal of nursing [Am J Nurs] 2020 Apr; Vol. 120 (4), pp. 23.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372646 Publication Model: Print Cited Medium: Internet ISSN: 1538-7488 (Electronic) Linking ISSN: 0002936X NLM ISO Abbreviation: Am J Nurs Subsets: Core Clinical (AIM); MEDLINE; Nursing
MeSH Terms :
Infusions, Intravenous*
Antibodies, Monoclonal, Humanized/*therapeutic use
Breast Neoplasms/*drug therapy
Camptothecin/*analogs & derivatives
Immunoconjugates/*therapeutic use
Antibodies, Monoclonal, Humanized/adverse effects ; Camptothecin/adverse effects ; Camptothecin/therapeutic use ; Female ; Humans ; Immunoconjugates/adverse effects
Czasopismo naukowe
Tytuł :
New Esophageal Cancer Indication for Pembrolizumab.
Autorzy :
Aschenbrenner DS; Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: .
Pokaż więcej
Źródło :
The American journal of nursing [Am J Nurs] 2019 Nov; Vol. 119 (11), pp. 21.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372646 Publication Model: Print Cited Medium: Internet ISSN: 1538-7488 (Electronic) Linking ISSN: 0002936X NLM ISO Abbreviation: Am J Nurs Subsets: Core Clinical (AIM); MEDLINE; Nursing
MeSH Terms :
Infusions, Intravenous*
Survival*
Antibodies, Monoclonal, Humanized/*therapeutic use
Esophageal Neoplasms/*drug therapy
Clinical Trials as Topic ; Humans
Czasopismo naukowe
Tytuł :
High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans.
Autorzy :
Ross C; Department of Psychiatry, Boston Children's Hospital, Boston, MA USA. E-MAIL: .
Jain R
Bonnett CJ
Wolfson P
Pokaż więcej
Źródło :
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists [Ann Clin Psychiatry] 2019 Nov; Vol. 31 (4), pp. 271-279.
Typ publikacji :
Journal Article; Observational Study
Journal Info :
Publisher: Frontline Medical Communications Country of Publication: United States NLM ID: 8911021 Publication Model: Print Cited Medium: Internet ISSN: 1547-3325 (Electronic) Linking ISSN: 10401237 NLM ISO Abbreviation: Ann Clin Psychiatry Subsets: MEDLINE
MeSH Terms :
Infusions, Intravenous*
Ketamine/*therapeutic use
Stress Disorders, Post-Traumatic/*drug therapy
Veterans/*statistics & numerical data
Adult ; Aged ; Dissociative Disorders/psychology ; Female ; Humans ; Male ; Middle Aged ; Psychiatric Status Rating Scales/statistics & numerical data ; Self Report ; Stress Disorders, Post-Traumatic/epidemiology ; Surveys and Questionnaires ; Treatment Outcome ; Veterans/psychology
Czasopismo naukowe
Tytuł :
The Impact of IV Electrolyte Replacement on the Fluid Balance of Critically Ill Surgical Patients.
Autorzy :
Wang AS
Dhillon NK
Linaval NT
Rottler N
Yang AR
Margulies DR
Ley EJ
Barmparas G
Pokaż więcej
Źródło :
The American surgeon [Am Surg] 2019 Oct 01; Vol. 85 (10), pp. 1171-1174.
Typ publikacji :
Journal Article
Journal Info :
Publisher: SAGE Publications in association with Southeastern Surgical Congress Country of Publication: United States NLM ID: 0370522 Publication Model: Print Cited Medium: Internet ISSN: 1555-9823 (Electronic) Linking ISSN: 00031348 NLM ISO Abbreviation: Am Surg Subsets: MEDLINE
MeSH Terms :
Critical Illness*
Surgical Procedures, Operative*
Water-Electrolyte Balance*
Electrolytes/*administration & dosage
Infusions, Intravenous/*methods
Calcium/administration & dosage ; Diuretics/administration & dosage ; Female ; Fluid Therapy/adverse effects ; Fluid Therapy/methods ; Humans ; Infusions, Intravenous/statistics & numerical data ; Intensive Care Units ; Magnesium Sulfate/administration & dosage ; Male ; Middle Aged ; Phosphorus/administration & dosage ; Potassium/administration & dosage ; Retrospective Studies
Czasopismo naukowe
Tytuł :
A rapid and simple UPLC method for serum vancomycin determination in pediatric patients undergoing continuous infusion or intermittent infusion of vancomycin.
Autorzy :
Zhang M; Beijing Municipal Key Laboratory of Child Development and Nutriomics, Capital Institute of Pediatrics, Beijing, 100020, China.
Huang X; Clinical Central Laboratory, Capital Institute of Pediatrics, Beijing, 100020, China.
Yahui W; Intensive Care Unit, Capital Institute of Pediatrics, Beijing, 100020, China.
Shi C; Intensive Care Unit, Capital Institute of Pediatrics, Beijing, 100020, China.
Pei P; Clinical Central Laboratory, Capital Institute of Pediatrics, Beijing, 100020, China.
Yang J; Department of neurology, Capital Institute of Pediatrics, Beijing, 100020, China.
Dong Q; Intensive Care Unit, Capital Institute of Pediatrics, Beijing, 100020, China. Electronic address: .
Cui X; Clinical Central Laboratory, Capital Institute of Pediatrics, Beijing, 100020, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2019 Sep 10; Vol. 174, pp. 214-219. Date of Electronic Publication: 2019 May 29.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE
MeSH Terms :
Infusions, Intravenous*
Anti-Bacterial Agents/*blood
Chromatography, High Pressure Liquid/*methods
Vancomycin/*blood
Anti-Bacterial Agents/administration & dosage ; Calibration ; Child ; Child, Preschool ; Drug Monitoring/methods ; Female ; Humans ; Infant ; Linear Models ; Male ; Methicillin-Resistant Staphylococcus aureus ; Quality Control ; Reproducibility of Results ; Staphylococcal Infections/drug therapy ; Vancomycin/administration & dosage
Czasopismo naukowe
Tytuł :
Extended drip infusion of peripheral parental nutrition containing amino acids might be associated with Bacillus cereus bloodstream infection.
Autorzy :
Shiota A; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Pharmacy, Aichi Medical University Hospital, Japan.
Asai N; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Japan.
Koizumi Y; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Japan.
Watanabe H; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Japan.
Sakata M; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan.
Kurumiya A; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan.
Takahashi T; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan.
Muramatsu Y; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan.
Hagihara M; Department of Molecular Epidemiology and Disease Control, Aichi Medical University, Japan.
Suematsu H; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan.
Yamagishi Y; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Japan.
Mikamo H; Department of Infection Control and Prevention, Aichi Medical University Hospital, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Japan. Electronic address: .
Pokaż więcej
Źródło :
American journal of infection control [Am J Infect Control] 2019 Sep; Vol. 47 (9), pp. 1154-1156. Date of Electronic Publication: 2019 Apr 30.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Mosby Country of Publication: United States NLM ID: 8004854 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3296 (Electronic) Linking ISSN: 01966553 NLM ISO Abbreviation: Am J Infect Control Subsets: MEDLINE
MeSH Terms :
Drug Contamination*
Amino Acids/*adverse effects
Bacillus cereus/*isolation & purification
Bacteremia/*etiology
Gram-Positive Bacterial Infections/*etiology
Infusions, Intravenous/*adverse effects
Parenteral Nutrition/*adverse effects
Amino Acids/administration & dosage ; Bacteremia/microbiology ; Cross Infection ; Gram-Positive Bacterial Infections/microbiology ; Humans ; Infusions, Intravenous/methods ; Japan ; Parenteral Nutrition/methods
Czasopismo naukowe
Tytuł :
Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis.
Autorzy :
Calcanes G; New York Cancer & Blood Specialists, East Setauket, New York (Mr Calcanes and Dr Vacirca). George Calcanes, BS, RN, is chief clinical officer at New York Cancer & Blood Specialists, where he manages an extensive oncology practice with infusion suites for outpatient chemotherapy. He institutes new chemotherapy regimens, clinics, and services for a large patient population, coordinating between clinical staff and pharmaceutical companies for optimal patient care. Jeffrey L. Vacirca, MD, FACP, is chief executive officer, managing partner, and director of clinical research at New York Cancer & Blood Specialists. He is also medical director for the International Oncology Network in Frisco, Texas; president of Community Oncology Alliance; and president of the National Translational Research Group in East Setauket, NY. His specialties include breast, prostate, and complicated cancers.
Vacirca JL
Pokaż więcej
Źródło :
Journal of infusion nursing : the official publication of the Infusion Nurses Society [J Infus Nurs] 2019 Sep/Oct; Vol. 42 (5), pp. 260-263.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101124170 Publication Model: Print Cited Medium: Internet ISSN: 1539-0667 (Electronic) Linking ISSN: 15331458 NLM ISO Abbreviation: J Infus Nurs Subsets: Nursing
MeSH Terms :
Infusions, Intravenous*
Antiemetics/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Aprepitant/*administration & dosage
Neoplasms/*drug therapy
Neurokinin-1 Receptor Antagonists/*administration & dosage
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Humans ; Male ; Nausea/chemically induced ; Nausea/prevention & control ; Neoplasms/complications ; Retrospective Studies ; Vomiting/chemically induced ; Vomiting/prevention & control
Czasopismo naukowe
Tytuł :
Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued.
Autorzy :
Politei J; Fundation for the Study of Neurometabolic Diseases, FESEN, Argentina. Electronic address: .
Pokaż więcej
Źródło :
Molecular genetics and metabolism [Mol Genet Metab] 2020 Aug; Vol. 130 (4), pp. 227-229. Date of Electronic Publication: 2020 Jun 06.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Academic Press Country of Publication: United States NLM ID: 9805456 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-7206 (Electronic) Linking ISSN: 10967192 NLM ISO Abbreviation: Mol. Genet. Metab. Subsets: MEDLINE
MeSH Terms :
Betacoronavirus/*pathogenicity
Continuity of Patient Care/*standards
Coronavirus Infections/*prevention & control
Enzyme Replacement Therapy/*standards
Fabry Disease/*therapy
Home Infusion Therapy/*standards
Lung Diseases, Obstructive/*prevention & control
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Adult ; Continuity of Patient Care/organization & administration ; Continuity of Patient Care/statistics & numerical data ; Coronavirus Infections/complications ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Enzyme Replacement Therapy/statistics & numerical data ; Fabry Disease/complications ; Fabry Disease/diagnosis ; Female ; Home Infusion Therapy/statistics & numerical data ; Humans ; Infection Control/standards ; Infusions, Intravenous ; Isoenzymes/administration & dosage ; Lung Diseases, Obstructive/diagnosis ; Lung Diseases, Obstructive/etiology ; Male ; Middle Aged ; Pneumonia, Viral/complications ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; Recombinant Proteins/administration & dosage ; Severity of Illness Index ; Time Factors ; alpha-Galactosidase/administration & dosage
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Prospective evaluation of aldosterone LC-MS/MS-specific cutoffs for the saline infusion test.
Autorzy :
Fries CM; Medical Department III, Endocrinology, Nephrology, Rheumatology, University Hospital of Leipzig, Leipzig, Germany.
Bae YJ; Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, University of Leipzig, Leipzig, Germany.
Rayes N; Endocrine Surgery, Department for Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital of Leipzig, Leipzig, Germany.
Sandner B; Medical Department III, Endocrinology, Nephrology, Rheumatology, University Hospital of Leipzig, Leipzig, Germany.
Isermann B; Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, University of Leipzig, Leipzig, Germany.
Stumvoll M; Medical Department III, Endocrinology, Nephrology, Rheumatology, University Hospital of Leipzig, Leipzig, Germany.
Fagotto V; Department of Medicine IV, Klinikum der Universität, Ludwig-Maximilians-Universität, München, Germany.
Reincke M; Department of Medicine IV, Klinikum der Universität, Ludwig-Maximilians-Universität, München, Germany.
Bidlingmaier M; Department of Medicine IV, Klinikum der Universität, Ludwig-Maximilians-Universität, München, Germany.
Mandy V; Leipzig Research Center for Civilization Diseases (LIFE Child), University of Leipzig, Leipzig, Germany.
Kratzsch J; Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, University of Leipzig, Leipzig, Germany.
Fenske WK; Medical Department III, Endocrinology, Nephrology, Rheumatology, University Hospital of Leipzig, Leipzig, Germany.; Integrated Research and Treatment Centre for Adiposity Diseases, Department of Medicine, University of Leipzig, Leipzig, Germany.
Pokaż więcej
Źródło :
European journal of endocrinology [Eur J Endocrinol] 2020 Aug; Vol. 183 (2), pp. 191-201.
Typ publikacji :
Journal Article
Journal Info :
Publisher: BioScientifica Ltd Country of Publication: England NLM ID: 9423848 Publication Model: Print Cited Medium: Internet ISSN: 1479-683X (Electronic) Linking ISSN: 08044643 NLM ISO Abbreviation: Eur. J. Endocrinol. Subsets: MEDLINE
MeSH Terms :
Aldosterone/*blood
Hyperaldosteronism/*blood
Hyperaldosteronism/*diagnosis
Saline Solution/*pharmacology
Adrenal Glands/diagnostic imaging ; Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Captopril/pharmacology ; Chromatography, High Pressure Liquid ; Female ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Prospective Studies ; Reference Values ; Reproducibility of Results ; Saline Solution/administration & dosage ; Sensitivity and Specificity ; Tandem Mass Spectrometry ; Young Adult
Czasopismo naukowe
Tytuł :
Effect of phenylephrine infusion on hypotension induced by the beach chair position: A prospective randomized trial.
Autorzy :
Ko MJ; Department of Anesthesiology and Pain Medicine.
Kim H; Department of Anesthesiology and Pain Medicine.
Lee HS; Department of Anesthesiology and Pain Medicine.
Lee SJ; Department of Anesthesiology and Pain Medicine.
Park YH; Department of Anesthesiology and Pain Medicine.
Bang JY; Department of Orthopedic Surgery, Haeundae Paik Hospital of Inje University, Busan, Republic of Korea.
Lee KH; Department of Anesthesiology and Pain Medicine.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jul 10; Vol. 99 (28), pp. e20946.
Typ publikacji :
Journal Article; Randomized Controlled Trial
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Hypotension/*etiology
Hypotension/*prevention & control
Intraoperative Complications/*etiology
Intraoperative Complications/*prevention & control
Patient Positioning/*adverse effects
Phenylephrine/*administration & dosage
Aged ; Female ; Humans ; Hypotension/epidemiology ; Incidence ; Infusions, Intravenous ; Male ; Middle Aged ; Prospective Studies ; Single-Blind Method
Czasopismo naukowe
Tytuł :
Baseline characteristics, diagnostic efficacy, and peri-examinational safety of IV gadoteric acid MRI in 148,489 patients.
Autorzy :
Braun J; Department of Radiology, Charité - University Medicine, Berlin, Germany.
Busse R; Department of Health Care Management, Faculty of Economics and Management, Berlin University of Technology, Berlin, Germany.
Darmon-Kern E; Guerbet, Roissy CDG Cedex, France.
Heine O; Guerbet GmbH, Sulzbach, Germany.
Auer J; Department of Radiology, Charité - University Medicine, Berlin, Germany.
Meyl T; Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University of Bern, Bern, Switzerland.
Maurer M; Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University of Bern, Bern, Switzerland.
Hamm B; Department of Radiology, Charité - University Medicine, Berlin, Germany.
de Bucourt M; Department of Radiology, Charité - University Medicine, Berlin, Germany.
Pokaż więcej
Źródło :
Acta radiologica (Stockholm, Sweden : 1987) [Acta Radiol] 2020 Jul; Vol. 61 (7), pp. 910-920. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji :
Journal Article; Multicenter Study
Journal Info :
Publisher: Sage Country of Publication: England NLM ID: 8706123 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0455 (Electronic) Linking ISSN: 02841851 NLM ISO Abbreviation: Acta Radiol Subsets: MEDLINE
MeSH Terms :
Magnetic Resonance Imaging*
Contrast Media/*administration & dosage
Contrast Media/*adverse effects
Meglumine/*administration & dosage
Meglumine/*adverse effects
Organometallic Compounds/*administration & dosage
Organometallic Compounds/*adverse effects
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Child, Preschool ; Female ; Germany ; Humans ; Infant ; Infusions, Intravenous ; Male ; Middle Aged ; Product Surveillance, Postmarketing ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
Autorzy :
Monk BJ; Arizona Oncology (US Oncology Network), Phoenix, AZ, USA; University of Arizona, Phoenix, AZ, USA; Creighton University, Phoenix, AZ, USA. Electronic address: .
Coleman RL; US Oncology Network, The Woodlands, TX, USA.
Moore KN; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA.
Herzog TJ; University of Cincinnati Cancer Institute, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Secord AA; Duke Cancer Institute, Duke University Health System, Durham, NC, USA.
Matulonis UA; Dana-Farber Cancer Institute, Boston, MA, USA.
Slomovitz BM; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Guntupalli SR; University of Colorado at Denver, Aurora, CO, USA.
O'Malley DM; The Ohio State University, James Cancer Center, Columbus, OH, USA.
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 Jul; Vol. 158 (1), pp. 34-36. Date of Electronic Publication: 2020 Apr 29.
Typ publikacji :
Editorial
Journal Info :
Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol. Oncol. Subsets: MEDLINE
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Coronavirus Infections/*prevention & control
Ovarian Neoplasms/*drug therapy
Ovarian Neoplasms/*virology
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Poly(ADP-ribose) Polymerase Inhibitors/*administration & dosage
Administration, Oral ; Betacoronavirus/isolation & purification ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Female ; Humans ; Infusions, Intravenous ; Organoplatinum Compounds/administration & dosage ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Opinia redakcyjna
Tytuł :
Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic.
Autorzy :
Geskin LJ; Department of Dermatology, Columbia University Irving Medical Center, New York, New York. Electronic address: .
Trager MH; Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
Aasi SZ; Department of Dermatology, Stanford Medicine, Stanford, California.
Bickers DR; Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
Carvajal RD; Division of Hematology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Nghiem P; Department of Dermatology, University of Washington Medical Center, Seattle, Washington.
Taback B; Department of Surgery, Columbia University Irving Medical Center, New York, New York.
Zeitouni NC; Department of Dermatology, University of Arizona College of Medicine, Phoenix, Arizona.
Samie FH; Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Jul; Vol. 83 (1), pp. 295-296. Date of Electronic Publication: 2020 May 06.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J. Am. Acad. Dermatol. Subsets: MEDLINE
MeSH Terms :
Betacoronavirus/*pathogenicity
Coronavirus Infections/*prevention & control
Dermatology/*standards
Medical Oncology/*standards
Pandemics/*prevention & control
Pneumonia, Viral/*prevention & control
Skin Neoplasms/*therapy
Betacoronavirus/immunology ; Chemotherapy, Adjuvant/standards ; Coronavirus Infections/epidemiology ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Dermatology/methods ; Humans ; Immunotherapy/adverse effects ; Immunotherapy/standards ; Infection Control/standards ; Infusions, Intravenous/standards ; Medical Oncology/methods ; Mohs Surgery/standards ; Neoadjuvant Therapy/standards ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; Risk Assessment/standards ; Skin/pathology ; Skin Neoplasms/immunology ; Skin Neoplasms/pathology ; Telemedicine/standards
SCR Disease Name :
COVID-19
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Hospital Pharmacy Compounding against COVID-19 pandemic.
Transliterated Title :
La farmacotecnia hospitalaria frente a la COVID-19.
Autorzy :
Alonso-Herreros JM; Servicio de Farmacia Hospitalaria, Hospital Los Arcos Mar Menor, Pozo Aledo, Murcia. España. .
Berisa-Prado S; Servicio de Farmacia Hospitalaria, Instituto Oftalmológico Fernández-Vega, Oviedo (Asturias). España. .
Cañete-Ramírez C; Servicio de Farmacia, Hospital Universitari Vall d'Hebron, Barcelona. España. .
Dávila-Pousa C; Servicio de Farmacia, Complexo Hospitalario Universitario, Pontevedra. España. .
Flox-Benítez MDP; Servicio de Farmacia, Hospital Universitario Santa Cristina, Madrid. España. .
Ladrón de Guevara-García M; Unidad de Gestión Clínica de Farmacia, Hospital Universitario Virgen del Rocío, Sevilla. España. .
López-Cabezas C; Servei de Farmàcia, Hospital Clínic, Barcelona. España. .
Martín de Rosales-Cabrera AM; Servicio de Farmacia, Hospital Universitario Fundación Alcorcón, Alcorcón (Madrid). España. .
Ramos-Martínez B; Servicio de Farmacia, Hospital Universitario de la Princesa, Madrid. España. .
Pokaż więcej
Źródło :
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2020 Jun 12; Vol. 44 (7), pp. 49-52. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Sociedad Española de Farmacia Hospitalaria Country of Publication: Spain NLM ID: 9440679 Publication Model: Electronic Cited Medium: Internet ISSN: 2171-8695 (Electronic) Linking ISSN: 11306343 NLM ISO Abbreviation: Farm Hosp Subsets: MEDLINE
MeSH Terms :
Betacoronavirus*
Drug Compounding*
Pandemics*
Coronavirus Infections/*drug therapy
Pharmacy Service, Hospital/*organization & administration
Pneumonia, Viral/*drug therapy
Administration, Oral ; Antiviral Agents/supply & distribution ; Antiviral Agents/therapeutic use ; Blood Component Transfusion ; Disinfection ; Drug Administration Routes ; Drug Interactions ; Drug Stability ; Equipment Contamination/prevention & control ; Excipients ; Forecasting ; Home Care Services ; Humans ; Hydroxychloroquine/administration & dosage ; Hydroxychloroquine/chemistry ; Infusions, Intravenous ; Lopinavir/administration & dosage ; Personal Protective Equipment/supply & distribution ; Platelet-Rich Plasma ; Ritonavir/administration & dosage ; Solutions
SCR Disease Name :
COVID-19
SCR Protocol :
COVID-19 drug treatment
SCR Organism :
severe acute respiratory syndrome coronavirus 2
Czasopismo naukowe
Tytuł :
Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study.
Autorzy :
Awad WB; Department of Pharmacy, King Hussein Cancer Center, P.O. Box 1269, Al-Jubeiha, Amman, 11941, Jordan. .
Asaad A; Department of Pharmacy, King Hussein Cancer Center, P.O. Box 1269, Al-Jubeiha, Amman, 11941, Jordan.
Al-Yasein N; Department of Pharmacy, King Hussein Cancer Center, P.O. Box 1269, Al-Jubeiha, Amman, 11941, Jordan.
Najjar R; Department of Pharmacy, King Hussein Cancer Center, P.O. Box 1269, Al-Jubeiha, Amman, 11941, Jordan.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Jun 05; Vol. 20 (1), pp. 400. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :
Journal Article
Journal Info :
Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect. Dis. Subsets: MEDLINE
MeSH Terms :
Antifungal Agents/*therapeutic use
Pentamidine/*therapeutic use
Pneumonia, Pneumocystis/*prevention & control
Adolescent ; Adult ; Antifungal Agents/adverse effects ; Antifungal Agents/pharmacology ; Comorbidity ; Female ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Pentamidine/adverse effects ; Pentamidine/pharmacology ; Pneumocystis carinii/drug effects ; Pneumonia, Pneumocystis/diagnosis ; Pneumonia, Pneumocystis/microbiology ; Retrospective Studies ; Transplantation, Autologous ; Transplantation, Homologous ; Young Adult
Czasopismo naukowe
Tytuł :
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.
Autorzy :
Minard-Colin V; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Aupérin A; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Pillon M; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Burke GAA; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Barkauskas DA; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Wheatley K; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Delgado RF; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Alexander S; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Uyttebroeck A; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Bollard CM; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Zsiros J; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Csoka M; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Kazanowska B; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Chiang AK; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Miles RR; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Wotherspoon A; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Adamson PC; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Vassal G; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Patte C; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Gross TG; From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) - all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology-Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children's National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children's Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).
Pokaż więcej
Corporate Authors :
European Intergroup for Childhood Non-Hodgkin Lymphoma
Children’s Oncology Group
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jun 04; Vol. 382 (23), pp. 2207-2219.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N. Engl. J. Med. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Antineoplastic Agents, Immunological/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, B-Cell/*drug therapy
Rituximab/*administration & dosage
Adolescent ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Humans ; Infections/etiology ; Infusions, Intravenous ; Kaplan-Meier Estimate ; Lymphoma, B-Cell/mortality ; Male ; Neutropenia/chemically induced ; Progression-Free Survival ; Rituximab/adverse effects
Czasopismo naukowe
Tytuł :
Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.
Autorzy :
Man S; Department of Neurology and Cerebrovascular Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
Xian Y; Duke Clinical Research Institute, Duke University, Durham, North Carolina.
Holmes DN; Duke Clinical Research Institute, Duke University, Durham, North Carolina.
Matsouaka RA; Duke Clinical Research Institute, Duke University, Durham, North Carolina.; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
Saver JL; Department of Neurology, University of California, Los Angeles.
Smith EE; Hotchkiss Brain Institute, Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Bhatt DL; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts.
Schwamm LH; Comprehensive Stroke Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Fonarow GC; Division of Cardiology, University of California, Los Angeles.
Pokaż więcej
Źródło :
JAMA [JAMA] 2020 Jun 02; Vol. 323 (21), pp. 2170-2184.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Time-to-Treatment*
Fibrinolytic Agents/*administration & dosage
Patient Readmission/*statistics & numerical data
Stroke/*drug therapy
Stroke/*mortality
Tissue Plasminogen Activator/*administration & dosage
Aged ; Aged, 80 and over ; Brain Ischemia/drug therapy ; Brain Ischemia/etiology ; Cause of Death ; Female ; Follow-Up Studies ; Humans ; Incidence ; Infusions, Intravenous ; Male ; Proportional Hazards Models ; Retrospective Studies ; Thrombolytic Therapy
Czasopismo naukowe
Tytuł :
The effect of a low-dose naloxone infusion on the incidence of respiratory depression after intrathecal morphine administration for major open hepatobiliary surgery: a randomised controlled trial.
Autorzy :
Cosgrave D; Department of Anaesthesia, St. Vincent's University Hospital, Dublin, Ireland.
Vencken S; Clinical Research Centre, University College Dublin, Ireland.
Galligan M; Clinical Research Centre, University College Dublin, Ireland.
McGuinness S; Department of Anaesthesia, St. Vincent's University Hospital, Dublin, Ireland.; Department of Anaesthesia, the National Maternity Hospital, Dublin, Ireland.
Soukhin E; Department of Anaesthesia, Auckland City Hospital, Auckland, New Zealand.
McMullan V; Department of Anaesthesia, Tallaght University Hospital, Dublin, Ireland.
Nair S; Liver transplantation and cardiac anaesthesia, Kings College Hospital NHS Trust, London, UK.
Puttappa A; Department of Anaesthesia, Addenbrookes Hospital, Cambridge University Hospital NHS Trust, Cambridge, UK.
Boylan J; Department of Anaesthesia, St. Vincent's University Hospital, Dublin, Ireland.
Hussain R; Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland.
Conlon N; Department of Anaesthesia, St. Vincent's University Hospital, Dublin, Ireland.
Doran P; Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Vic., Australia.
Nichol A; Department of Intensive Care Medicine, St. Vincent's University Hospital, Dublin, Ireland.; Clinical Research Centre, St. Vincent's University Hospital, Dublin, Ireland.; Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Vic., Australia.
Pokaż więcej
Źródło :
Anaesthesia [Anaesthesia] 2020 Jun; Vol. 75 (6), pp. 747-755. Date of Electronic Publication: 2019 Dec 02.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0370524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2044 (Electronic) Linking ISSN: 00032409 NLM ISO Abbreviation: Anaesthesia Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Digestive System Diseases/*surgery
Morphine/*adverse effects
Naloxone/*therapeutic use
Pain, Postoperative/*drug therapy
Respiratory Insufficiency/*chemically induced
Respiratory Insufficiency/*prevention & control
Adult ; Aged ; Analgesics, Opioid/administration & dosage ; Analgesics, Opioid/adverse effects ; Analgesics, Opioid/therapeutic use ; Biliary Tract Surgical Procedures ; Female ; Humans ; Incidence ; Infusions, Intravenous ; Injections, Spinal ; Liver/surgery ; Male ; Middle Aged ; Morphine/administration & dosage ; Morphine/therapeutic use ; Naloxone/administration & dosage ; Narcotic Antagonists/administration & dosage ; Narcotic Antagonists/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Autorzy :
Thanarajasingam G; Division of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: .
Leonard JP; Division of Hematology and Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA.
Witzig TE; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Blum KA; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Bartlett NL; Washington University School of Medicine, Washington University, St Louis, MO, USA.
Flowers CR; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pitcher BN; Alliance Statistics and Data Center, Duke University, Durham, NC, USA.
Jung SH; Alliance Statistics and Data Center, Duke University, Durham, NC, USA.
Atherton PJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Tan A; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Novotny PJ; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
Dueck AC; Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ, USA.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Jun; Vol. 7 (6), pp. e490-e497.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
Journal Info :
Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
MeSH Terms :
Angiogenesis Inhibitors/*toxicity
Antineoplastic Combined Chemotherapy Protocols/*toxicity
Hematologic Neoplasms/*drug therapy
Lenalidomide/*toxicity
Lymphoma, Follicular/*drug therapy
Angiogenesis Inhibitors/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Tolerance/physiology ; Fatigue/chemically induced ; Fatigue/classification ; Fatigue/epidemiology ; Humans ; Infusions, Intravenous ; Lenalidomide/adverse effects ; Neutropenia/chemically induced ; Neutropenia/classification ; Neutropenia/epidemiology ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Thrombosis/chemically induced ; Thrombosis/classification ; Thrombosis/epidemiology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies